Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) dropped 4.1% during mid-day trading on Wednesday . The company traded as low as $3.21 and last traded at $3.27, with a volume of 117,369 shares changing hands. The stock had previously closed at $3.41.

DRNA has been the subject of a number of research reports. Chardan Capital initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Monday, April 4th. They set a “neutral” rating and a $5.00 target price for the company. Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Thursday, June 30th. Jefferies Group reissued a “buy” rating and set a $19.00 target price on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. Stifel Nicolaus decreased their target price on shares of Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Finally, Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $11.95.

The firm’s 50-day moving average price is $3.42 and its 200-day moving average price is $5.26. The firm’s market cap is $68.91 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.10. Analysts forecast that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.